CIP2A in Cancer: Molecular Mechanisms, Signalling Networks and Clinical Implications

Cancerous inhibitor of protein phosphatase 2A (CIP2A) is an oncoprotein that is frequently overexpressed in many cancers and can be associated with cancer progression, poor prognosis, and treatment resistance. CIP2A was initially characterised as an inhibitor of protein phosphatase 2A (PP2A), thereby inhibiting the dephosphorylation and degradation of the transcription factor c-Myc. However, more recent evidence suggests that CIP2A has broader functions in cell cycle progression, genomic stability, and DNA damage repair. CIP2A is regulated at multiple levels, including transcriptional, post-transcriptional and post-translational mechanisms, allowing integration with several oncogenic signalling pathways. Elevated CIP2A expression has been reported in numerous haematological and solid malignancies, where it is frequently associated with poor clinical outcomes. Growing evidence supports the use of CIP2A as a prognostic biomarker, and its central role in tumour biology has established the CIP2A-PP2A interaction as a promising therapeutic target. Although challenges remain, including incomplete structural characterisation and the absence of clinically approved CIP2A-targeted therapies, continued research in biomarker development and drug discovery highlights the potential of CIP2A in personalised cancer treatment to improve patient outcomes.

Authors

Institutions

Publication Details

Journal
Biomolecules
Published
2026-11-18
DOI
https://doi.org/10.3390/biom16111677
Primary Topic
Cancer Mechanisms and Therapy
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

CIP2A in Cancer: Molecular Mechanisms, Signalling Networks and Clinical Implications

Ammar A. Basabrain, Claire Lucas, Abigail H. Burnett
Biomolecules
Cancer Mechanisms and Therapy
article

CIP2A in Cancer: Molecular Mechanisms, Signalling Networks and Clinical Implications

Ammar A. Basabrain, Claire Lucas, Abigail H. Burnett
article en

Abstract

Cancerous inhibitor of protein phosphatase 2A (CIP2A) is an oncoprotein that is frequently overexpressed in many cancers and can be associated with cancer progression, poor prognosis, and treatment resistance. CIP2A was initially characterised as an inhibitor of protein phosphatase 2A (PP2A), thereby inhibiting the dephosphorylation and degradation of the transcription factor c-Myc. However, more recent evidence suggests that CIP2A has broader functions in cell cycle progression, genomic stability, and DNA damage repair. CIP2A is regulated at multiple levels, including transcriptional, post-transcriptional and post-translational mechanisms, allowing integration with several oncogenic signalling pathways. Elevated CIP2A expression has been reported in numerous haematological and solid malignancies, where it is frequently associated with poor clinical outcomes. Growing evidence supports the use of CIP2A as a prognostic biomarker, and its central role in tumour biology has established the CIP2A-PP2A interaction as a promising therapeutic target. Although challenges remain, including incomplete structural characterisation and the absence of clinically approved CIP2A-targeted therapies, continued research in biomarker development and drug discovery highlights the potential of CIP2A in personalised cancer treatment to improve patient outcomes.

BiomoleculesVol. 16(11)
University of Chester (GB), University of Liverpool (GB), King Abdulaziz University (SA), King Abdulaziz Medical City (SA), Countess of Chester Hospital (GB)
Good health and well-being
Cancer Mechanisms and Therapy
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon